The American College of Physicians (ACP) is recommending more conservative use of transfusions and erythropoiesis-stimulating agents (ESAs) in anemia patients with heart disease. But the authors of the new clinical practice guidelines, published in the Annals of Internal Medicine, acknowledge that the evidence base is too flimsy to support firm conclusions. “Overall,” wrote the authors, “despite the epidemiologic…
You are browsing articles on the topic of Heart Failure Archives - CardioExchange
Questioning Digoxin Use for Patients with Systolic HF (17 Oct 2013)
James Freeman discusses his research group’s evaluation of the contemporary effectiveness and safety of digoxin therapy among adults with newly diagnosed systolic heart failure.
The FDA’s Circulatory System Devices Panel sent a mixed message to the FDA today about the CardioMEMS Champion HF Pressure Measurement System. The small implantable device provides daily pulmonary artery pressure measurements to guide physicians in their treatment of patients with congestive heart failure. In December 2011 the same panel voted 9-1 that the device was safe, 7-3 that…
How Well Do Standard ECG Criteria Detect RV Hypertrophy? (10 Oct 2013)
Isaac Whitman and Steven Kawut discuss their study of the sensitivity and specificity of electrocardiographic criteria in screening for MRI-detected right ventricular hypertrophy in patients without clinical cardiovascular disease.
New Drug for Pulmonary Hypertension Approved by FDA (9 Oct 2013)
The FDA approved on Tuesday a new drug for pulmonary hypertension. Bayer HealthCare’s riociguat (brand name Adempas) was approved for two indications: the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class the treatment of adults with pulmonary arterial hypertension (PAH) to…
Nesiritide Does Not Increase Diuresis in ADHF Patients (30 Sep 2013)
Stephen Gottlieb discusses his research group’s analysis of ASCEND-HF data, which shows that nesiritide does not increase urine output in patients with ADHF.
Higher Physician Volume Leads to Lower Mortality in HF (27 Sep 2013)
Karen Joynt discusses her research group’s study of the relationship between physician volume, clinical outcomes, and costs among patients with HF.
Study Raises Questions About Digoxin Use Today (24 Sep 2013)
Digoxin is one of the oldest medicines in the cardiovascular arsenal. When William Withering identified it as the active ingredient in the foxglove plant more than 200 years ago, he was only codifying a longstanding folk remedy for heart failure, or “dropsy” as it was known then. Digoxin fully entered the modern era with the…
A New Standard For Pulmonary Hypertension Trials (11 Sep 2013)
Recently the New England Journal of Medicine published the SERAPHIN trial studying the effects of macitentan, a new endothelin receptor antagonist, in pulmonary arterial hypertension (PAH). This was a well-conducted study in 742 patients with PAH randomized to placebo, a low dose of macitentan (3mg once a day) and a high dose of macitentan (10mg once…